BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 271,200 shares, a decrease of 49.4% from the March 31st total of 535,900 shares. Based on an average trading volume of 345,100 shares, the short-interest ratio is currently 0.8 days.
BioCardia Stock Performance
Shares of NASDAQ BCDA traded up $0.01 during mid-day trading on Friday, reaching $0.38. The company’s stock had a trading volume of 20,244 shares, compared to its average volume of 317,581. The stock has a 50-day moving average of $0.41 and a two-hundred day moving average of $0.50. The stock has a market capitalization of $10.12 million, a P/E ratio of -0.67 and a beta of 1.47. BioCardia has a 1-year low of $0.32 and a 1-year high of $2.92.
BioCardia (NASDAQ:BCDA – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. BioCardia had a negative net margin of 2,425.79% and a negative return on equity of 3,638.68%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.20 million. Analysts predict that BioCardia will post -0.42 EPS for the current fiscal year.
Insiders Place Their Bets
Institutional Inflows and Outflows
A hedge fund recently raised its stake in BioCardia stock. CM Management LLC boosted its stake in shares of BioCardia, Inc. (NASDAQ:BCDA – Free Report) by 74.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 600,000 shares of the company’s stock after buying an additional 257,000 shares during the quarter. CM Management LLC owned 2.78% of BioCardia worth $258,000 as of its most recent SEC filing. Institutional investors own 20.57% of the company’s stock.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
Further Reading
- Five stocks we like better than BioCardia
- Market Cap Calculator: How to Calculate Market Cap
- 3 Stocks Leading the U.S. Agriculture Comeback
- Best Stocks Under $5.00
- How to Use Put Debit Spreads to Profit From Falling Stocks
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.